Clinical Trial Update: Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, tolerability, and pharmacokinetics of idelalisib in adults with myelofibrosis receiving ruxolitinib; study terminated with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Idelalisib (idelalisib)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Gilead Sciences | Conditions: Myelofibrosis | Phase 1 | Status: TERMINATED | Results posted: 2020-08-14